Overview

Vaginal Antibody Safety Trial: Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV)

Status:
Completed

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and pharmacokinetics of MB66, a monoclonal antibody film for vaginal application that is being developed to potentially reduce the transmission of herpes simplex virus (HSV) and human immunodeficiency virus (HIV).

Phase:

Phase 1

Details

Lead Sponsor:

LeafBio, Inc.
ZabBio Inc.

Collaborators:

Boston University
National Institute of Allergy and Infectious Diseases (NIAID)
The Miriam Hospital

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins